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Abstract
Introduction Patients with primary operable oestrogen receptor
(ER) negative (-) breast cancer account for about 30% of all
cases and generally have a worse prognosis than ER-positive
(+) patients. Nevertheless, a significant proportion of ER- cases
have favourable outcomes and could potentially benefit from a
less aggressive course of therapy. However, identification of
such patients with a good prognosis remains difficult and at
present is only possible through examining histopathological
factors.
Methods Building on a previously identified seven-gene
prognostic immune response module for ER- breast cancer, we
developed a novel statistical tool based on Mixture Discriminant
Analysis in order to build a classifier that could accurately
identify ER- patients with a good prognosis.
Results We report the construction of a seven-gene expression
classifier that accurately predicts, across a training cohort of
183 ER- tumours and six independent test cohorts (a total of
469 ER- tumours), ER- patients of good prognosis (in test sets,
average predictive value = 94% [range 85 to 100%], average
hazard ratio = 0.15 [range 0.07 to 0.36] p < 0.000001)
independently of lymph node status and treatment.
Conclusions This seven-gene classifier could be used in a
polymerase chain reaction-based clinical assay to identify ER-
patients with a good prognosis, who may therefore benefit from
less aggressive treatment regimens.
Introduction
Oestrogen receptor (ER) negative (-) breast cancer accounts
for about 30% of all breast cancer cases and generally has a
worse prognosis compared with ER positive (+)disease [1,2].
Nevertheless, a significant proportion of ER- cases have
shown a favourable outcome and could potentially benefit
from a less aggressive course of therapy [3]. Reliable identifi-
cation of such ER- patients with a good prognosis is, however,
difficult and at present only possible through examining his-
topathological factors.
Recently, attempts have been made to explain the observed
clinical heterogeneity of ER- disease in terms of gene expres-
sion signatures [4-7]. However, most of these studies clearly
indicated the difficulty of identifying a prognostic gene expres-
sion signature for ER- disease [4,6,7], unlike ER+ breast can-
cer where a multitude of alternative prognostic signatures
have been identified [3,8-11]. Nevertheless, using an integra-
tive analysis of gene expression microarray data from three
untreated (no chemotherapy) ER- breast cancer cohorts (a
total of 186 patients) [3,8,10] and a novel feature selection
method [11], it was possible to identify a seven-gene immune
response expression module associated with goodPage 1 of 11
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C1QA: complement component 1, q subcomponent, A chain; CI: confidence intervals; CT: chemotherapy; ER: oestrogen receptor; HER2: human 
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clinical heterogeneity in ER- disease can be explained on the
basis of mRNA expression levels [5]. Specifically, overexpres-
sion of this immune response gene module identified a sub-
class of basal ER- breast cancer, about 25% of all ER- cases,
with a reduced risk of distant metastasis (Hazard ratio [HR] =
0.49; range 0.29 to 0.83; p = 0.009) compared with ER-
cases without overexpression of this module [5], a result that
was validated in two independent untreated test cohorts (58
ER- samples) [9,12].
The important role that immune system-related gene expres-
sion signatures play in breast cancer prognosis has been fur-
ther supported by four recent reports [13-16]. Specifically,
one study reported that high expression of lymphocyte-associ-
ated genes identifies a good prognosis subgroup within lymph
node negative (LN-) human epidermal growth factor receptor
2 positive (HER2+) breast cancer [13]. A further study
focused on LN- breast cancer and identified a prognostic B-
cell metagene signature, confirming that overexpression of this
signature correlated with good prognosis in ER- breast can-
cer, while underexpression correlated with good prognosis in
ER+ breast cancer [14]. A similar contrasting result between
ER- and ER+ breast cancer was also found by deriving a gene
expression signature for lymphocytic infiltration (LI) and dem-
onstrating its positive and negative association with good
prognosis in ER- and ER+ disease, respectively [15]. All these
results are consistent with our findings and highlight the
importance of stratifying breast cancer patients into ER+ and
ER- subtypes before associations with clinical outcome can
be derived [5,16].
The discovery and construction of a molecular classifier that
can robustly identify ER- patients with a good prognosis is
important for two main reasons. First, identification of ER-
patients with a good prognosis based on histopathological
predictors like LN status or Adjuvant! is far from optimal [17].
Second, reliable identification of ER- patients of good progno-
sis could help guide the management of ER- patients further,
by providing less aggressive treatment regimens for such
patients. Building on our previous results [5] here we report on
the construction of a seven-gene prognostic classifier and fur-
ther validate this single-sample predictor across six (four
untreated and two partially treated) independent ER- breast
cancer cohorts: 'UPP' [12], 'JRH-2' [9], 'UNC248' [18], 'CAL'
[19], 'Loi' [20] and 'Kreike' [6]. This therefore confirms the
validity of this classifier in more than 469 ER- patients.
Materials and methods
Linear and quadratic discriminant analysis
Before discussing Mixture Discriminant Analysis (MDA), it is
convenient to briefly review Linear Discriminant Analysis (LDA)
and Quadratic Discriminant Analysis (QDA) [21]. We assume
that we have a training data set X of dimension p × N, where
p is the number of dimensions (ie, genes) and N is the number
of training samples (ie, tumour samples). We also assume that
we have a test set Y of dimension p × n and that we have C
phenotype classes among the training set samples.
In the training process of discriminant analysis one attempts to
learn parameters that specify the clusters associated with
each of the phenotype classes. In the maximum likelihood
framework, one learns parameters (π, θ) = (πk, θk = 1,..., C)
such that the likelihood function
is maximised. In the above, fk denotes the probability function
that specifies the probability that the observation xi is gener-
ated from cluster k, πk denotes the weight of this cluster and
θk parameterises the cluster. The optimisation of the likelihood
is performed using the EM-algorithm, subject to the constraint
that , yielding estimates .
Having estimated the parameters, we can now classify a test
sample y using Bayes' Theorem as follows. The probability that
y belongs to class k is just the posterior probability p(k|y),
which by Bayes' Theorem can be written as
Assigning y to the class which maximises this posterior prob-
ability (the maximum probability criterion) minimises the
expected misclassification error. Thus,
k = class(y) = max{p(c|y)|c = 1,..., C} (3)
To compute the posterior probabilities one needs to estimate
the functions fk or, if the functional form is prespecified, the
parameters θk. The simplest functional approximation one can
make is to assume that the clusters are multivariate Gaussians,
so that
where μk is the mean and Σk the covariance matrix of the Gaus-
sian. If, furthermore, we assume that the covariance matrices
are identical for each cluster (ie, Σk = Σ ∀ k), then the classifi-
cation function becomes a linear function of y, known as LDA.
In the more general case where the covariance matrices of
each class are allowed to differ, the classification function is a
quadratic form of the y and the analysis is known as QDA.
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The assumption that a phenotype class is best modelled by a
multivariate Gaussian is often violated. In the context of gene-
expression analysis, gene expression profiles often exhibit bi-
or multimodality, even when restricted to one phenotype class
[5]. Similarly, gene expression profiles typically also have
longer tails than Gaussians. In such circumstances, it seems
more appropriate to model each fk as a mixture of multivariate
Gaussians, since any general density can be approximated by
such a mixture. Therefore, one assumes that
where the number of Gaussians to use for phenotype label k
is given by Gk. This number may or may not be specified in
advance resulting in a variety of different implementations. In
ordinary MDA [22], one assumes that Gk is known in advance
for each class k and that the covariance matrices are all iden-
tical (ie, Σkj = Σ). However, these assumptions are not neces-
sary and instead one can use the training data to learn the best
mixture model fit for each phenotype class using for example
the Bayesian Information Criterion (BIC) [21] or a variational
Bayesian framework for model selection [23]. This model
selection step is a cluster-inference procedure that yields esti-
mates for(τkj,μkj,Σkj, Gk), from which classification of test sam-
ples proceeds as before using the maximum probability
criterion. Therefore, MDA is a direct generalisation of LDA and
QDA and may reduce to these if the data does not support
multiple components per phenotype class [21].
Classification in heterogeneous cancers: the MDAhet 
classifier
Using mixtures of Gaussians, the densities of each phenotype
class can be estimated more accurately. Thus, provided that
the inferred Gaussian components are biologically meaningful,
this approach should in general lead to an improved classifica-
tion performance. However, the implicit assumption in MDA is
that we are still interested in classifying samples into the C
phenotype classes, whereas in certain circumstances we may
be only interested in classifying into certain subtypes within
the phenotype classes. Therefore, while in MDA one allows for
heterogeneity of each phenotype label by estimating the den-
sity of each class as a mixture of Gaussians, classification is
subsequently performed into each phenotype class. On the
other hand, it is possible to classify samples into the Gaussian
subcomponents inferred for each phenotype class, a variation
of MDA called Heterogeneous Mixture Discriminant Analysis
(MDAhet), because this explicitly takes the heterogeneity of
each phenotype class into account by attempting to classify
the samples into these subcomponents.
As an example, consider the case of two phenotype classes
with MDA predicting two Gaussian components for each
class. Thus, training data is used to learn the parameters and
weights for four Gaussian clusters and classification of test
samples is subsequently performed via the Bayes' classifier
(equation 3) on these four subclasses. Note therefore that in
MDAhet, the cluster-inference step of MDA is used to define
the classes for which classification is then performed. Since
these inferred classes make up subtypes of the original phe-
notype labels, this classification framework explicitly takes the
heterogeneity of the phenotypes into account.
In the context of cancer gene-expression studies it has been a
problem in certain cancers to derive reliable prognostic classi-
fiers as is the case for ER- breast cancer. Typically, in the con-
text of prognosis one would expect discriminative gene-
expression profiles to exhibit bimodal distributions with the two
modes mapping roughly to the two prognostic groups (good
and poor) [11]. However, as previously shown [5], the best
candidate gene-expression prognostic markers can also
exhibit bimodal (or multimodal) profiles (ie, mixtures of Gaus-
sians) within a given prognostic class, indicating that these
phenotypes are themselves heterogeneous and that classifi-
cation analysis should attempt to take this heterogeneity
explicitly into account. Thus, in such circumstances the pro-
posed classifier MDAhet seems the more appropriate classifi-
cation scheme to use.
Time-dependent negative predictive value analysis
Following the work by Heagerty and colleagues [24], we esti-
mate time-dependent sensitivity SE(t) and specificity SP(t) val-
ues using Kaplan-Meier estimators for the predicted
subclasses. In our context, we assume that samples have been
classified into two groups, so that the predictor X = 1 predicts
poor prognosis, while X = 0 predicts good prognosis (ie, the
'good-up' group) Thus,
where (t) denotes the Kaplan-Meier estimator for the
overall survival function, while (t|X = c) denotes the Kap-
lan-Meier survival estimate for the particular subgroup X = c (c
= 1, 2) [24]. In our context, however, the most important per-
formance measure is the negative prective value (NPV), since
this is the probability of correctly identifying a patient with a
good prognosis. Adapting the same methods as used by
Heagerty and colleagues [24] we can obtain time-dependent
estimates for the NPV and positive predictive value (PPV) sim-
ply as:
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The seven-gene immune response module validates in 
six external cohorts
Applying a feature selection method designed to remove false
positives [11] to an integrated expression data set of 186
untreated ER- samples across 5007 genes [3,8,10], we previ-
ously identified a total of 22 prognostic genes, seven of which
were associated with immune response functions (XCL2,
HLA-F, C1QA, TNFRSF17, SPP1, IGLC2, LY9) [5]. Further-
more, mapping the seven-genes into those available on two
external platforms we were able to separate two independent
untreated populations of ER- breast cancer patients [9,12]
into two subgroups with statistically significant differences in
survival outcome [5]. Specifically, samples overexpressing this
module had significantly better clinical outcomes, as meas-
ured by absence of a poor outcome event (disease-specific
death or the surrogate distant metastasis if the former was
unavailable) (Figures 1a, b).
These results motivated us to investigate the prognostic role
of the immune response-module further in four additional ER-
data sets for which gene expression and clinical data were
available [6,18-20]. Using the same partitioning around
medoids algorithm to separate each of these additional inde-
pendent cohorts into two subgroups we were able to confirm
the prognostic role of the immune response-module across a
total of 469 ER- tumours (Figures 1c to 1f). Given that overex-
pression of the immune response-module consistently identi-
fied a good prognosis subgroup of ER- breast cancer, we
asked if we could derive a robust single-sample prognostic
NPV t S t X
PPV t S t X
KM
KM
( )= ( | = 0)
( )= 1 ( | = 1)
ˆ
ˆ
−
Figure 1
Heatmaps of seven-gene immune response-modulesaps of seven-gene i mun  response-modules. Heatmaps of gene expression of the seven-gene immune response-module for the train-
ing and six test cohorts (red = high relative expression, green = low). Samples are clustered into two groups according to the partitioning around 
medoids algorithm [28] (purple = group overexpressing the immune response-module, yellow = group underexpressing the immune response-mod-
ule). Clinical outcome as defined by a disease-specific death event (or distant metastasis if the former is not available) is also shown (black = poor, 
grey = good, white = missing data). Note that in some cases not all seven genes could be mapped to the external platform. C1QA = complement 
component 1, q subcomponent, A chain; HLA-F = major histocompatibility complex, class I, F; IGLC2 = immunoglobulin lambda constant 2; LY9 = 
lymphocyte antigen 9; TNFRSF17 = tumour necrosis factor receptor superfamily member 17; SPP1 = secreted phosphoprotein 1 (osteopontin); 
XCL2 = chemokine (C motif) ligand 2.Page 4 of 11
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Deriving the prognostic classifier
To derive a single-sample prognostic classifier we first applied
a mixture discriminant classifier to the same training set of 186
ER- patients and across the seven identified genes. The heter-
ogeneity of the good-prognosis phenotype, as shown by the
gene expression patterns of the immune response-module
(Figure 1), suggested to us that MDA [21] would be an appro-
priate classification method to use, since it is designed to work
for such heterogeneous phenotypes. Specifically, the MDA
classifier estimates, from the training data, densities for each
of the good and poor prognosis phenotypes as mixtures of two
Gaussians (Figure 2). The choice of two Gaussians to model
each phenotype was not arbitrary but followed from the appli-
Figure 2
The MDA and MDAhet classifier   et classifier. Four two-dimensional projections of the seven-dimensional Mixture Discriminant Analysis (MDA) and Heterogene-
ous Mixture Discriminant Analysis (MDAhet) classifiers. Scatterplots show projections of the training expression data (183 oestrogen receptor neg-
ative samples) onto arbitrarily chosen two-dimensional subspaces spanned by the genes HLA-F and IGLC2, LY9 and TNFRSF17, SPP1 and XCL2, 
and IGLC2 and C1QA. Codings: black = poor outcome, grey = good outcome, triangle = training samples classified into the good prognosis sub-
group defined by overexpression of seven-gene module 'good-up', circle = training samples not classified into 'good-up' group. In addition, the 
means and covariance-curves of the two Gaussians that approximate each of the poor (black ellipses) and good outcome (grey ellipses) classes are 
shown. C1QA = complement component 1, q subcomponent, A chain; HLA-F = major histocompatibility complex, class I, F; IGLC2 = immunoglob-
ulin lambda constant 2; LY9 = lymphocyte antigen 9; TNFRSF17 = tumour necrosis factor receptor superfamily member 17; SPP1 = secreted 
phosphoprotein 1 (osteopontin); XCL2 = chemokine (C motif) ligand 2.Page 5 of 11
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mal number of Gaussians to use [23] (data not shown). Thus,
using the training data, patients with a good prognosis were
divided up into two groups, one with high relative expression
of the immune response-genes (the 'good-up' group) and
another with relative low expression (the 'good-down' group).
A similar subdivision was performed for the poor prognosis
patients to yield 'poor-up' and 'poor-down' subgroups. The
training process involves learning the mean expression vec-
tors, covariance matrices and weights for each of the four sub-
groups (Table 1).
Evaluation of the prognostic classifier: MDAhet versus 
MDA
Having estimated the parameters for each of the phenotypes,
external samples can then be classified by applying the MDA
to the test sample's gene expression profile, yielding probabil-
ities of the sample belonging to each phenotype class, and
subsequently using the maximum probability criterion for class
assignment. Since each phenotype class is modelled as a mix-
ture of two Gaussians (Figure 2), class assignment can also
be made on the four subclasses, a novel variation of MDA
called MDAhet because this explicitly takes the heterogeneity
of each phenotype in the classification process into account.
This novel variation of MDA is crucial as it allows for a more
reliable identification of good prognosis samples (ie, the NPV).
In detail, MDAhet assigns a test sample with a seven-gene
expression profile y to one of the four subclasses c (c = 1, 2,
3, 4) using the maximum probability criterion
where G denotes the seven-dimensional multivariate Gaus-
sian and the parameters  are estimated from the
training set (Table 1).
The classification distribution of samples from the six external
cohorts into the four subclasses as determined by MDAhet
showed that test samples classified most often into the 'poor-
down' and 'good-up' classes (Table 2). Since samples falling
into the 'good-down' and 'poor-down' categories could not be
discriminated in terms of prognosis (a sign that these sub-
classes are not distinguishable on the basis of the expression
of these seven genes) we can pool these together in order to
compare more objectively the predicted proportions with
those estimated from the training set. This revealed that for
four cohorts, JRH-2 (8 vs. 16), CAL (13 vs. 33), UNC248 (28
vs. 56) and Loi (13 vs. 27), the 'good-up' group is about half
the size of the pooled 'down' group (Table 2), which is consist-
ent with the relative proportions estimated from the training set
(0.28 vs. 0.63). For the other two cohorts, relative proportions
still did not deviate markedly from the training set proportions,
although some deviations might be expected due to inherent
cohort differences.
Validation of MDAhet in external cohorts
To evaluate the performance of the MDAhet classifier in the
training and test cohorts we used several different measures
and models of prognostic separation, depending on the varia-
ble of clinical outcome used. As binary outcome we used
absence or presence of a disease-specific death event, or the
Table 1
The Heterogeneous Mixture Discriminant Analysis (MDAhet) 
classifier.
good-down good-up poor-down poor-up
HLA-F -0.31 0.65 -0.29 0.40
IGLC2 -0.56 0.98 -0.46 0.68
LY9 -0.29 0.58 -0.52 1.12
TNFRSF
17
-0.41 0.97 -0.58 0.59
SPP1 0.01 -0.38 0.47 -0.57
XCL2 -0.36 0.67 -0.41 0.58
C1QA -0.39 0.79 -0.40 0.57
0.74 0.74 0.58 0.58
 ∝ I 0.31 0.28 0.32 0.09
Estimated mean expression profiles , covariance matrices  and 
weights  for the four subgroups, as estimated from the training 
set. Note that the optimal covariance matrices were all proportional 
to the identity matrix  ∝ I and are thus summarised by a single 
value, the variance of expression of the corresponding cluster. 
C1QA, complement component 1, q subcomponent, A chain; HLA-
F, major histocompatibility complex, class I, F; IGLC2, 
immunoglobulin lambda constant 2; LY9, lymphocyte antigen 9; 
TNFRSF17, tumour necrosis factor receptor superfamily member 17; 
SPP1, secreted phosphoprotein 1 (osteopontin); XCL2, chemokine 
(C motif) ligand 2.
μˆ
ˆΣ
πˆ
μˆ ˆΣ
πˆ
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Table 2
Classification of test samples.
Test cohort Size good-down good-up poor-down poor-up
UPP 34 4 14 16 0
JRH-2 24 5 8 11 0
CAL 46 13 13 20 0
Kreike 97 18 35 41 3
UNC248 85 28 28 28 1
Loi 40 8 13 19 0
Distribution of test samples into the four subclasses by the 
Heterogeneous Mixture Discriminant Analysis (MDAhet) classifier.
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Since this does not take time dependence of events into
account, binary outcome was also used at four years after sur-
gery adapting methods for time-dependent receiver operator
curve (ROC) analysis [24]. In addition, we considered contin-
uous outcome in full stratified Cox-proportional hazard regres-
sion models, where stratification was performed on a per
cohort basis to take inter-cohort differences in the types of sur-
vival data (ie, whether disease-specific survival or distant
metastasis) into account.
Performance indicators based on the binary outcome meas-
ures are shown in Table 3. The most important performance
indicator in our context is the NPV, since this represents the
Table 3
Performance measures of seven-gene Heterogeneous Mixture Discriminant Analysis (MDAhet) classifier
Training set Test Sets
Cohort NKI2+EMC+NCH UPP JRH-2 CAL Kreike UNC248 Loi
Cohort size 186 34 24 46 97 85 40
Annotated 183 31 24 46 71 80 34
Good prognosis (%) 59 81 75 67 76 74 76
Poor prognosis (%) 41 19 25 33 24 26 24
Chemotherapy (%) 0 0 0 67 0 66 0
MDA
NPV (%) 74 92 93 69 83 74 100
PPV (%) 55 28 56 35 29 27 40
SE (%) 69 83 83 53 71 38 100
SP (%) 61 48 78 52 44 63 54
MDAhet
NPV (%) 80 100 100 100 85 92 100
PPV (%) 51 30 37 45 29 36 35
SE (%) 84 100 100 100 76 90 100
SP (%) 44 44 44 42 41 42 42
NPV at 4 years (%) 83 100 100 100 88 93 100
PPV at 4 years (%) 42 24 33 35 25 45 35
SE at 4 years (%) 83 100 100 100 79 88 100
SP at 4 years (%) 44 42 43 37 40 45 43
LN
NPV (%) 61 84 NA 85 NA 85 76
PPV (%) 50 30 NA 46 NA 37 0a
SE (%) 27 50 NA 80 NA 71 0a
SP (%) 81 70 NA 55 NA 58 100a
NPV at 4 years (%) 67 88 NA 90 NA 82 77
PPV at 4 years (%) 39 37 NA 38 NA 47 0a
SE at 4 years (%) 25 84 NA 85 NA 69 0a
SP at 4 years (%) 80 74 NA 53 NA 60 100a
aLoi's cohort consists only of LN- samples. The table summarises performance indicators of the seven-gene MDAhet classifier and lymph node status (LN) 
across oestrogen receptor negative (ER-) training and test sets. For each cohort, we also give the number of tumours (cohort size), number of clinically 
annotated tumours (annotated), the percentage of good and poor prognosis patients (as defined by disease-specific death or distant metastasis event) 
and the percentage of patients treated with chemotherapy. NPV, PPV, SE and SP are evaluated at four years and at end of study. NPV, negative 
predictive value (precision for good prognosis); PPV, positive predictive value (precision for poor prognosis); SE, sensitivity; SP, specificity.Page 7 of 11
(page number not for citation purposes)
Breast Cancer Research    Vol 10 No 4    Teschendorff and Caldas probability of correctly identifying a good prognosis patient. As
shown, the NPV was very high with average values of 0.8 in the
training sets and 0.96 in the test sets (range 0.85 to 1).
Indeed, a significant improvement over simple predictions
based on a priori known proportions was observed in all test
sets (Table 3). In line with these results, sensitivity values were
also very high with average values of 0.84 in training sets and
0.94 in test sets (range 0.76 to 1). Results evaluated at four
years after surgery were, as expected, not markedly different,
indicating that the prognostic classifier performs equally well
in terms of short-term survival outcomes (Table 3).
Stratified Cox-regression models further confirmed the much
better prognosis of the predicted subclass overexpressing the
immune response-module relative to samples classified as
poor prognosis (Table 4). Specifically, samples classified as
good prognosis with overexpression of the immune response-
module ('good-up' group) have less than half the risk of a poor
outcome event (death or distant metastasis) relative to sam-
ples classified as poor prognosis, a result that we found to be
independent of LN status and chemotherapy (Table 4). Note
that four of the test cohorts were untreated (no chemotherapy)
populations (Table 3), such as the training set itself, confirming
the prognostic relevance of the classifier, and that chemother-
apy itself was not prognostic in the two partially treated popu-
lations (Table 4).
Kaplan-Meier survival curves stratified according to the type of
survival data (disease-specific death or distant metastasis) fur-
ther confirmed the better prognosis of the predicted 'good-up'
group (Figure 3). These survival curves further show that the
classifier in the test sets is unable to discriminate the good
prognosis samples that do not overexpress the immune
response-module ('good-down') from the poor outcome sam-
ples. This result is expected since the seven-gene module is
hypothesised to only identify a particular subgroup of good
prognosis [5].
Since the maximum probability criterion assigns test samples
to classes without regard to how large the maximal posterior
class probabilites are, we tested the robustness of our results
by only classifying samples passing a minimum probability
threshold. For a probability threshold of 0.3 (already significant
compared with the minimum possible maximal probability of 1/
4 = 0.25), 94% of all test samples passed this threshold, indi-
cating that our results are indeed robust. For a threshold of
0.4, we found 68%of samples were classifiable and results
were still in line with those reported for the minimum threshold
of 0.25 (data not shown).
Discussion
Based on the seven genes we had identified previously as
defining an immune response-related prognostic module in
ER- breast cancer, we have now constructed a single-sample
classifier and have validated it in six external, independent ER-
cohorts, four of which were untreated populations. Remarka-
bly, we find that overexpression of this immune response-mod-
ule considerably reduces the risk of disease-specific death or
distant metastasis in both untreated and partially untreated
ER- populations (HR = 0.15; 95% confidence interval 0.07 to
0.36; p < 10-6) (Table 4). Importantly, we also found that this
association is independent of LN status (Table 4). In terms of
binary outcome measures, the classifier shows clinical prom-
ise with consistently high NPV values across all test cohorts,
even when time-dependent outcome measures are taken into
account (Table 3). For example, the NPV and sensitivity values
Table 4
Stratified Cox-regression model of seven-gene Heterogeneous Mixture Discriminant Analysis (MDAhet) classifier
Training set Combined test set
Annotated 183 286
MDAhet 0.29 (0.16–0.56) p = 0.0002 0.15 (0.07–0.36) p < 0.000001
LN 1.31 (0.73–2.33) p = 0.36 3.25 (1.61–6.58) p = 0.001
CT NA 0.68 (0.34–1.39) p = 0.29
LN+MDAhet
MDAhet 0.29 (0.15–0.55) p = 0.0002 0.06 (0.01–0.27) p = 0.0002
LN 1.59 (0.81–3.11) p = 0.18 3.68 (1.32–10.13) p = 0.012
CT+MDAhet
MDAhet NA 0.27 (0.15–0.48) p = 0.00001
CT NA 0.76 (0.27–2.13) p = 0.6
Stratified Cox-proportional hazards regression performance of the seven-gene MDAhet classifier, lymph node status (LN) and chemotherapy (CT) 
across oestrogen receptor-negative training and test sets, with strata defined by cohorts. For the univariate analysis, Hazard ratio (HR), 95% 
confidence intervals (CI) and LR-test p-value are given. In the multivariate models, p-values quoted are from the corresponding Wald test.Page 8 of 11
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Available online http://breast-cancer-research.com/content/10/4/R73at four years after surgery were 100% in four of the six cohorts
and in all cases larger than 85%. Thus, the classifier could
potentially be used for identifying high-grade ER- patients that
may benefit from a less agressive or nonexistent course of
chemotherapy.
The remarkably high NPV values in the test cohorts, however,
raise some important questions. First, we found that the per-
formance in the test sets was better than in the training set
(Tables 3 and 4). While this is true for the NPV analysis, the
Cox-regression analysis also shows that the 95% confidence
intervals (CI) are overlapping. Therefore, statistically, there is
no discrepancy. In any case, a plausible explanation for why
the performance is slightly worse in the training set could be
related to the merging step involved in building the training set
[5]. By merging different microarray expression sets together
we gain power from the considerable increase in sample size;
however, merging may also compromise the accuracy of the
expression profiles, because these need to be renormalised
before merging is performed [5]. Therefore, it is entirely plau-
sible that small errors in the merging procedure may have
affected the classifier's performance in the training set. In this
context it is important to point out that the training set is only
used to derive a classifier and that the gold-standard
evaluation of any classifier is determined by its performance in
the test cohorts [25]. As shown here, the MDAhet classifier is
strongly prognostic across six totally independent breast can-
cer cohorts profiled on different array platforms.
A second important point relates to the nature of the MDAhet
classifier. As remarked in a previous study [9], in the context of
validating gene expression signatures across different array
platforms, some renormalisation is inevitable. Thus, our
MDAhet classifier is not strictly speaking a single-sample pre-
dictor because the gene expression value of a test sample
needs to be renormalised (a simple centering and scaling)
across all the test samples in the same cohort, before classifi-
cation is performed. However, this does not preclude the clas-
sifier from being a potential single-sample predictor because
in the clinical setting such platform differences would not exist
and so no normalisation step would be necessary. Hence, in
line with other classifiers presented in the literature [9,26] our
MDAhet classifier is also a single-sample predictor because,
modulo the normalisation step, the classification is performed
solely with information taken from the training set (Table 1).
Given the association of overexpressed immune response
related genes with good prognosis in ER- breast cancer, as
supported now by several studies [5,13-16], it is natural to ask
about the biological meaning of such overexpression. One
plausible explanation for the overexpression of immune
response genes in these tumours is a higher degree of LI,
because some of the genes involved are lymphocyte markers
Figure 3
Kaplan-Meier curves for MDAhet classifierl -Meier curves for MDAhet classifier. Kaplan-Meier survival curves for the three subclasses 'good-down' (light green), 'good-up' (dark 
green), 'poor-down' (blue), as predicted by the Heterogeneous Mixture Discriminant Analysis (MDAhet) classifier, in the training and combined test 
cohorts. The class 'poor-up' is not shown due to small sample size (Table 2). Hazard ratios (HR), 95% confience intervals (CI) and log-rank test p-
values are given for the predicted 'good-up' class relative to the predicted poor prognostic classes, as given by a stratified Cox-regression model 
with strata defined by cohorts. The Kaplan-Meier curves for each subclass is shown separately for disease-specific survival (solid lines) and distant 
metastasis (broken lines).Page 9 of 11
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Breast Cancer Research    Vol 10 No 4    Teschendorff and Caldas [13-15] and LI itself is associated with good prognosis in ER-
breast cancer patients [6,14,15]. However, there is also evi-
dence for a more complex role of the mRNA expression of
these genes [5]. First, it was found that the prognostic per-
formance of the seven-gene module previously reported [5]
was independent of LI. Second, it was shown that the good
prognosis class was heterogeneous with only about half of the
cases mapping closely to medullary breast cancer, a morpho-
logically distinct subclass associated with high LI and margin-
ally better prognosis as compared with the other ER- subtypes
(ie, the basal and the HER2+ subtypes) [5,27]. Thus, the best
prognosis is attained by the other half of the samples that are
not necessarily related to high LI and medullary breast cancer
[5]. All these findings are consistent with the marginal associ-
ation of LI or LI-associated gene expression with good progno-
sis in ER- breast cancer, as reported recently [6,13-15], and
suggest that only part of the overexpression of the immune
response-module is due to LI [5]. Lending further support to
this, it was also found that one gene member (SPP1) is con-
sistently underexpressed in patients with a good prognosis. To
conclude, we can therefore hypothesise that the MDAhet clas-
sifier and associated immune response-module may be identi-
fying another good prognosis ER- subset of tumours, but with
a significantly better prognosis than medullary high-LI breast
cancer (Tables 3 and 4). In any case, even if the expression
pattern of the immune response-module is entirely due to var-
iable LI, the MDAhet classifier appears to provide a much more
reliable prognostic classifier than LI-scores derived from
immunohistochemistry [6] or lymphocyte-specific gene
expression markers [14,15]. Further larger studies with relia-
ble LI data are required to answer these questions conclu-
sively [15].
Conclusion
We have derived a single-sample classifier for good prognosis
in ER- breast cancer with a high predictive value (in test sets,
mean NPV = 94%, range 85 to 100%) in six independent test
cohorts and validity in more than 469 patients, and which per-
forms independently of LN status. We propose to develop a
reverse transcriptase-polymerase chain reaction-based clini-
cal assay based on these seven genes to identify ER- patients
of good prognosis that may benefit from a less aggressive
course of chemotherapy.
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